Does an Automated Insulin Pump System Pay Off? What a Hong Kong Study Found

For people with Type 1 diabetes, choosing between insulin delivery methods involves more than just convenience—it's also about long-term health and cost. The MiniMed 780G is an automated insulin delivery (AID) system that adjusts insulin doses on its own based on blood sugar readings. But does it justify its cost compared to traditional approaches like multiple daily injections paired with continuous glucose monitoring (CGM)?

Researchers in Hong Kong decided to find out by modeling what would happen over decades if different groups of people used each approach.

The analysis used computer modeling to predict long-term outcomes and costs. Researchers looked at two groups: adults with diabetes that wasn't well-controlled (HbA1c of 8% or higher), and children and teenagers who started treatment before age 18.

They used real clinical trial data showing that the MiniMed 780G reduced HbA1c by about 1.54% from baseline, while injections plus CGM reduced it by about 0.2%. The analysis stretched predictions over 60 years and included both direct medical costs and the value of health improvements.

For adults, the cost to gain one additional year of healthy life with the automated system came to about USD $44,759 compared to the traditional approach. For children and teenagers, that figure was lower at USD $38,543—meaning the system offered proportionally more benefit in younger users.

The analysis also projected that using the automated system would prevent complications over time, including kidney disease, nerve damage, vision loss, and heart disease.

This study was designed for Hong Kong's healthcare system and used Hong Kong pricing data. Costs, insurance coverage, and how cost-effectiveness is judged vary significantly by country and region.

The findings apply specifically to people whose blood sugar control was not meeting targets at the start. Results may differ for those already well-controlled on other treatments.

Real-world experience also depends on factors the model can't fully capture, like how well someone can use the device, access to support, and individual health situations.

Source: Journal of diabetes science and technology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.